MERCK KGAA
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1668-01-01
- Employees
- 62.9K
- Market Cap
- $84.2B
- Website
- http://www.merckgroup.com/de
Efficacy and Safety of Crinone Versus Combination Medication (ACCESS)
- First Posted Date
- 2019-02-28
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 172
- Registration Number
- NCT03858049
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, China
L-PZQ ODT in Schistosoma Infected Children
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2019-02-19
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 288
- Registration Number
- NCT03845140
- Locations
- 🇰🇪
Kemri Kisumu, Kisumu, Kenya
🇨🇮Universitè de Cocody, Abidjan, Côte D'Ivoire
Effects of Cladribine Tablets on the PK of Microgynon®
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-11-19
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 28
- Registration Number
- NCT03745144
- Locations
- 🇵🇱
BioVirtus Research Site Sp, Otwock, Poland
🇩🇪St. Josef und St. Elisabeth Hospital gGmbH, Bochum, Germany
🇵🇱M.A. - LEK A.M.Maciejowscy SC., Katowice, Poland
Human Absorption, Distribution, Metabolism and Excretion (ADME) of [14C]-Evobrutinib
- First Posted Date
- 2018-10-30
- Last Posted Date
- 2020-07-07
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 6
- Registration Number
- NCT03725072
- Locations
- 🇳🇱
PRA Health Sciences, Groningen, Netherlands
Study of Avelumab and Cetuximab Plus Gemcitabine and Cisplatin in Participants With NSCLC
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-10-24
- Last Posted Date
- 2022-06-06
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 43
- Registration Number
- NCT03717155
- Locations
- 🇭🇺
Petz Aladar Megyei Oktato Korhaz - Pulmonologiai Osztaly, Gyor, Hungary
🇭🇺Tudogyogyintezet Torokbalint - Onkopulmonologiai es Jarobeteg centrum, Torokbalint, Hungary
🇪🇸Hospital Universitari Vall d'Hebron - Dept of Oncology, Barcelona, Spain
Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study of M5049 in Healthy Participants
- First Posted Date
- 2018-09-18
- Last Posted Date
- 2019-12-03
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 96
- Registration Number
- NCT03676322
- Locations
- 🇩🇪
Nuvisan GmbH, Neu-Ulm, Germany
Bioequivalence of TF3 and TF2 and Effect of Food on the PK of Tepotinib
- First Posted Date
- 2018-08-14
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 66
- Registration Number
- NCT03629223
- Locations
- 🇩🇪
Nuvisan GmbH, Neu-Ulm, Germany
Effect of Tepotinib on PK of CYP3A Substrate Midazolam
- First Posted Date
- 2018-08-14
- Last Posted Date
- 2023-07-28
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 12
- Registration Number
- NCT03628339
- Locations
- 🇩🇪
Nuvisan GmbH, Neu-Ulm, Germany
Retrospective Study to Estimate the Current Status of Patients With Non-Obstructive coroNary Artery Disease
Completed
- Conditions
- First Posted Date
- 2018-07-12
- Last Posted Date
- 2018-10-30
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 1600
- Registration Number
- NCT03584321
- Locations
- 🇩🇪
Please Contact the Merck KGaA Communication Center, Darmstadt, Germany
Glucophage® Extended Release (XR) 750 Milligram (mg) Indonesia Bioequivalence (BE) Study
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-07-11
- Last Posted Date
- 2019-11-25
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 48
- Registration Number
- NCT03583385
- Locations
- 🇮🇩
PT Equilab International, Jakarta, Indonesia
© Copyright 2024. All Rights Reserved by MedPath